Acute Promyelocytic Leukemia

APL is a particularly aggressive acute myeloid leukemia subtype associated with life-threatening coagulopathy. Prompt administration of all-trans retinoic acid (ATRA) is a core initial intervention when APL is suspected, while diagnostic evaluation proceeds. BMJ+1BMJAcute myeloid leukaemia - Symptoms, diagnosis and treatment | BMJ Best PracticeNatureAcute promyelocytic leukemia current treatment algorithms

Coordinate urgent hematology involvement and obtain the diagnostic material needed to establish acute leukemia subtype and guide subsequent therapy. Acute leukemia work-up should include review of the CBC with differential and peripheral-blood smear; bone marrow aspirate and trephine biopsy, cytogenetic analysis, and molecular genetic testing inform diagnosis, prognosis, and treatment. PubMed+1PubMedInitial Diagnostic Work-Up of Acute Leukemia: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists and American Society of Hematology Guideline - PMCBMJAcute myeloid leukaemia - Symptoms, diagnosis and treatment | BMJ Best Practice

The supplied sources establish the emergency role of ATRA but do not provide a source-supported U.S. dosing regimen, confirmatory assay workflow, or molecular-response schedule. Verify current product labeling and institutional leukemia protocols before prescribing.

AML diagnosis requires bone marrow aspirate and trephine biopsy assessment; cytogenetic and molecular genetic testing inform diagnostic classification, prognosis, and treatment selection. BMJBMJAcute myeloid leukaemia - Symptoms, diagnosis and treatment | BMJ Best Practice For acute leukemia more broadly, the pathologist should review recent or concurrent CBC values, leukocyte differentials, and a peripheral smear. PubMedPubMedInitial Diagnostic Work-Up of Acute Leukemia: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists and American Society of Hematology Guideline - PMC

APL-specific molecular confirmation is clinically consequential because treatment differs from other AML subtypes. The available sources identify molecular testing as part of AML evaluation but do not provide validated test characteristics, turnaround-time targets, or an assay-specific confirmatory strategy for suspected PML::RARA. Use the local hematopathology laboratory's urgent acute-leukemia pathway.

Presenting WBC count is a useful prognostic factor in APL. Standard-risk disease comprises low- and intermediate-risk categories with WBC count 10,000/µL or less; within this group, platelet count above or below 40 × 10^9/L distinguishes low from intermediate risk. High-risk APL is defined by presenting WBC count above 10,000/µL. NatureNatureAcute promyelocytic leukemia current treatment algorithms

This classification should be documented at presentation before treatment-related changes in leukocyte count obscure the baseline risk category. The supplied evidence does not specify an exact treatment regimen by risk group; use contemporary institutional or specialty guidance for regimen selection.

AML treatment is generally organized into induction and consolidation phases, with hematopoietic stem-cell transplantation and/or maintenance used selectively. BMJBMJAcute myeloid leukaemia - Symptoms, diagnosis and treatment | BMJ Best Practice In APL, management begins differently because prompt ATRA and correction of coagulopathy are prioritized at first suspicion. NatureNatureAcute promyelocytic leukemia current treatment algorithms

Treatment planning should account for baseline APL risk, early bleeding risk, evolving leukocyte count, organ function, treatment tolerance, and access to leukemia-specialist care. FDA guidance recognizes that AML drug development and treatment indications may apply to individual phases including maintenance and transplantation preparative regimens, underscoring that these phases require distinct objectives and evidence. fda+1fdaGuidance for Industry Acute Myeloid LeukemiafdaAcute Myeloid Leukemia: Developing Drugs and Biological Products for Treatment | FDA

The supplied sources do not provide source-supported doses or sequencing for arsenic trioxide, anthracycline-based therapy, cytoreductive therapy, corticosteroid prophylaxis or treatment for differentiation syndrome, transplantation, maintenance, or molecular surveillance. These decisions should follow current APL-specific protocols rather than extrapolation from non-APL AML regimens.

The defining early complication emphasized in the available evidence is life-threatening coagulopathy. Monitor coagulation parameters, fibrinogen, and platelet count closely enough to sustain the recommended transfusion targets, escalating blood-product support when values fall outside target. NatureNatureAcute promyelocytic leukemia current treatment algorithms

Avoid procedures that may precipitate bleeding during the coagulopathic presentation. Specifically, central-line placement, lumbar puncture, and leukapheresis should be avoided. NatureNatureAcute promyelocytic leukemia current treatment algorithms If an invasive procedure becomes unavoidable, individualize timing after hematology consultation and correction of coagulopathy; no procedural thresholds beyond the cited transfusion targets are provided in the supplied sources.